Trial Profile
A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Oct 2022
Price :
$35
*
At a glance
- Drugs Fosgemcitabine palabenamide (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms ACELARATE
- 01 Jan 2021 Status changed from suspended to completed.
- 13 Nov 2019 According to a NuCana media release, an update from this trial is expected in 2020.
- 27 Oct 2019 Planned End Date changed from 31 Dec 2020 to 1 Dec 2022.